Research programme: clindamycin implant - Novalar Pharmaceuticals

Drug Profile

Research programme: clindamycin implant - Novalar Pharmaceuticals

Alternative Names: Clindamycin-EVA

Latest Information Update: 04 Apr 2014

Price : $50

At a glance

  • Originator Harvard School of Dental Medicine; The Forsyth Institute
  • Developer Novalar Pharmaceuticals
  • Class
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Dental infections

Most Recent Events

  • 25 Jul 2007 Preclinical trials in Dental infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top